Instrument Inactif

Gouvernance Silence Therapeutics plc London S.E.

GB0008433350

Recherche biotechnologique et médicale

Cours en clôture London S.E. Autres places de cotation
- ^GBX	-

29/07	Légère baisse pour les actions européennes cotées aux États-Unis sous forme d'ADR lors de la séance de mercredi	MT
28/07	Les actions européennes cotées aux États-Unis sous forme d'ADR s'effritent lors de la séance de mardi	MT

Comité Exécutif: Silence Therapeutics plc

Dirigeant

Fonctions occupéesDepuis

Iain Ross

72 ans

Chief Executive Officer

01/12/2025

Marie Wikström Lindholm

Chief Tech/Sci/R&D Officer

01/12/2023

Steven Romano

66 ans

Chief Tech/Sci/R&D Officer

01/04/2023

Gem Hopkins

Investor Relations Contact	01/08/2020
Public Communications Contact	01/08/2020

J.P. Gabriel

Chief Tech/Sci/R&D Officer

01/11/2022

Curtis Rambaran

Chief Tech/Sci/R&D Officer

01/01/2021

Jaimin B. Shah

General Counsel

01/09/2025

Rhonda Hellums

54 ans

Director of Finance/CFO	01/02/2022
Corporate Secretary	18/12/2025

Composition du Conseil d'Administration: Silence Therapeutics plc

Administrateur

ComitésDepuis

Iain Ross

72 ans

Governance Committee Chair	01/07/2021
Nominating Committee Chair	01/07/2021
Audit Committee	29/10/2024
Compensation Committee	29/10/2024
Nominating Committee	31/01/2025

Tim McInerney

65 ans

Compensation Committee	01/04/2016
Governance Committee	01/04/2016
Nominating Committee	05/05/2025
Audit Committee Chair	01/04/2016
Audit Committee	05/05/2025
Compensation Committee Chair	05/05/2025

James Ede-Golightly

46 ans

Audit Committee	18/12/2025
Audit Committee Chair	01/04/2018
Compensation Committee Chair	01/04/2018
Compensation Committee	18/12/2025
Nominating Committee	18/12/2025

David Lemus

63 ans

Compensation Committee	21/06/2018
Nominating Committee
Audit Committee Chair	01/01/2020

Rhonda Hellums

54 ans

Director/Board Member

18/12/2025

Anciens Dirigeants et Administrateurs: Silence Therapeutics plc

Insider

Fonctions occupées

DepuisJusqu'au

Craig Tooman

Director/Board Member	21/02/2022	14/12/2025
Chief Executive Officer	21/02/2022	14/12/2025
Director of Finance/CFO	06/01/2021	21/02/2022
President	21/02/2022	14/12/2025

Michael Davidson

Director/Board Member	06/01/2021	11/08/2025
Independent Dir/Board Member	01/01/2022	11/08/2025

Eric Floyd

General Counsel

01/07/2020

01/01/2025

Alistair Gray

Director/Board Member	12/11/2015	01/05/2024
Independent Dir/Board Member	12/11/2015	01/05/2024

Gianine Esposito

Human Resources Officer

01/04/2024

John Strafford

Corporate Officer/Principal

01/05/2019

01/04/2023

Giles Campion

Director/Board Member	20/05/2020	01/04/2023
Chief Tech/Sci/R&D Officer	01/06/2019	01/04/2023

Jorgen Wittendorff

Corporate Officer/Principal

05/08/2019

06/02/2023

Eric Fink

Human Resources Officer

01/02/2022

01/11/2022

Mark Rothera

Director/Board Member	14/09/2020	21/02/2022
Chief Executive Officer	14/09/2020	21/02/2022
President	14/09/2020	21/02/2022

Robert Quinn

Director of Finance/CFO	09/01/2019	06/01/2021
Corporate Secretary	09/01/2019	06/01/2021

Alison Gallafent

Corporate Officer/Principal

01/02/2017

02/01/2020

David Solomon

Director/Board Member	20/08/2018	01/01/2020
Chief Executive Officer	20/08/2018	01/01/2020

Stephen Parker

Director/Board Member	16/10/2017	25/04/2019
Chairman	22/09/2015	16/10/2017
Independent Dir/Board Member	18/11/2013	25/04/2019

Andrew Richards

Director/Board Member	02/09/2016	20/08/2018
Chairman	20/08/2018	16/04/2019
Independent Dir/Board Member	02/09/2016	20/08/2018

David J. Ellam

Director/Board Member	18/07/2016	09/01/2019
Director of Finance/CFO	18/07/2016	09/01/2019
Corporate Secretary	18/07/2016	09/01/2019

Laura Roca-Alonso

Corporate Officer/Principal

01/01/2004

01/01/2019

Annalisa Jenkins

Chief Executive Officer	04/06/2018	20/08/2018
Chairman	16/10/2017	20/08/2018

Torsten Hoffmann

Chief Operating Officer

01/06/2017

21/06/2018

Ahmad Mortazavi

Director/Board Member	29/08/2012	04/06/2018
Chief Executive Officer	29/05/2013	04/06/2018
Corporate Officer/Principal	02/08/2012	29/05/2013

Linnea Corwin Elrington

Human Resources Officer

01/11/2017

Lucio Iannone

Corporate Officer/Principal

01/08/2014

30/09/2017

Michael Mulqueen

Corporate Officer/Principal

01/09/2017

Jörg Kaufmann

Chief Tech/Sci/R&D Officer

06/05/2010

14/09/2016

Tim Freeborn

Director/Board Member	08/10/2012	18/07/2016
Director of Finance/CFO	08/10/2012	18/07/2016
Corporate Secretary	08/10/2012	18/07/2016

Michael Khan

Director/Board Member	19/09/2012	17/06/2016
Chief Tech/Sci/R&D Officer	19/09/2012	17/06/2016

Lars Guldbæk Karlsson

Director/Board Member	05/01/2015	05/04/2016
Chief Tech/Sci/R&D Officer	05/01/2015	05/04/2016

Stuart J. M. Collinson

Director/Board Member

18/01/2016

05/04/2016

Simon Sturge

Director/Board Member	21/08/2013	18/01/2016
Chairman	19/11/2013	05/01/2015
Independent Dir/Board Member	21/08/2013	18/01/2016

Alastair Riddell

Director/Board Member	18/11/2013	05/01/2015
Chairman	18/11/2013	22/09/2015
Independent Dir/Board Member	18/11/2013	22/09/2015

Oliver von Stein

Chief Operating Officer

01/09/2014

01/08/2015

Jia Huey Cheng

Director/Board Member	29/05/2013	02/09/2014
Chief Operating Officer	19/11/2013	02/09/2014
Corporate Officer/Principal	29/05/2013	19/11/2013

Annie Cheng

Chief Operating Officer

02/09/2014

Jeremy Randall

Director/Board Member	01/07/2008	02/03/2010
Chairman	02/03/2010	18/11/2013

Klaus Giese

Chief Tech/Sci/R&D Officer

23/11/2010

18/11/2013

David Mack

Director/Board Member

08/01/2010

26/06/2013

Anthony David Sedgwick

Director/Board Member	21/09/2011	29/05/2013
Chief Executive Officer	21/09/2011	29/05/2013

Annette Clancy

Director/Board Member

01/07/2008

02/08/2012

Max Herrmann

Director of Finance/CFO	02/08/2012	02/08/2012
Corporate Secretary	02/08/2012	02/08/2012

Georg Buchner

Corporate Officer/Principal

08/11/2011

01/06/2012

Thomas Christély

Chief Executive Officer	20/09/2011	10/02/2012
Chief Operating Officer	-	20/09/2011

David C. U'Prichard

Director/Board Member

05/10/2009

31/12/2011

Philip Haworth

Director/Board Member	01/08/2011	01/08/2011
Chief Executive Officer	05/01/2010	01/08/2011

James Topper

Director/Board Member

06/01/2010

29/07/2011

Xiao Dong Yang

Corporate Officer/Principal

01/12/2009

01/05/2010

John Davies

Director of Finance/CFO	01/01/1996	01/03/2010
Corporate Secretary	01/01/1996	01/03/2010

Hugh Ronald Peter Reynolds

Director/Board Member

05/01/2010

Jeremy Curnock-Cook

Director/Board Member	05/01/2010	05/01/2010
Independent Dir/Board Member	05/01/2010	-

Bernd O. Wetzel

Director/Board Member

05/10/2009

05/01/2010

Barbara Ruskin

Corporate Officer/Principal

01/01/2010

Michael Riley

Corporate Officer/Principal

23/11/2010

Jeffery Scott Vick

Chief Executive Officer

27/07/2007

17/07/2008

Iain N. H. Rugheimer

Director/Board Member

30/06/2008

Eric Boyle

Chairman	01/11/1994	01/05/2004
Founder	01/11/1994	01/05/2004

Rozi Morris

Public Communications Contact

David A. Kennard

Chief Operating Officer

John Mark Lucas

General Counsel	-	-
Corporate Officer/Principal	05/10/2009	23/11/2010

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	10
Femme	1

Dont comité exécutif

Homme	7
Femme	1

Dont Administrateurs

Homme	4
Femme	1

Silence Therapeutics plc est une société mondiale de biotechnologie au stade clinique qui s’engage à transformer la vie des gens en neutralisant les maladies grâce à des médicaments de précision développés à partir d’une technologie exclusive d’ARNsi (ARN court interférent). La société s’appuie sur sa plateforme mRNAi GOLD pour créer des ARNsi conçus pour cibler et neutraliser avec précision les gènes associés à des maladies au niveau du foie. La société se concentre sur des domaines présentant des besoins médicaux non satisfaits importants, avec des programmes en cours de développement dans les domaines des maladies cardiovasculaires, de l’hématologie et des maladies rares. Le divesiran (SLN124) est son candidat-médicament siRNA détenu en propriété exclusive, conçu pour inhiber l’expression de la TMPRSS6 dans le foie. Le zerlasiran est une molécule d’ARNsi conçue pour le traitement des maladies cardiovasculaires associées à un taux élevé de Lp(a), une lipoprotéine présente dans le sang. Outre son portefeuille de produits cliniques détenus en propriété exclusive, la société dispose d’un troisième produit candidat à base d’ARNsi issu de sa plateforme mRNAi GOLD, actuellement en phase I de développement pour une indication non divulguée, dans le cadre de sa collaboration avec AstraZeneca.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société